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Abstract
Metastatic breast cancer cells are characterized by their high propensity to colonize the skeleton and form bone
metastases, causing major morbidity and mortality. Identifying key proteins involved in the osteotropic phenotype
would represent a major step toward the development of both new prognostic markers and new effective thera-
pies. Cell surface proteins differentially expressed in cancer cells are preferred potential targets for antibody-based
targeted therapies. In this study, using cell surface biotinylation and a mass spectrometric approach, we have com-
pared the profile of accessible cell surface proteins between the human breast cancer cell line MDA-MB-231 and
its highly osteotropic B02 subclone. This strategy allowed the identification of several proteins either up- or down-
regulated in the osteotropic cell line, and differential protein expressions were validated using antibody-based
techniques. Class I HLAs were down-regulated in the bone metastatic variant, whereas αvβ3 integrins, among
others, were consistently up-regulated in this latter cell line. These results show that comprehensive profiling of
the cell surface proteome of mother cancerous cell lines and derived organ-specific metastatic cell lines provides
an effective approach for the identification of potential accessible marker proteins for both prognosis and antibody-
based targeted therapies.
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Introduction
Metastases represent the major cause of morbidity for cancer pa-
tients, yet combating them represents a challenging task. Breast can-
cer has a strong predilection for spreading to the skeleton [1], and
almost three quarters of breast cancer patients with advanced disease
experience bone metastases. These bone metastases are associated
with substantial morbidity, including among others bone pain, path-
ologic fracture, neurologic deficit, and hypercalcemia. Identifying key
proteins involved in the osteotropic phenotype would represent a
major step toward the development of both new prognostic markers
and therapeutic improvements. With recent mass spectrometry–
based advances in biomarker discovery, as well as growing knowledge
of cellular pathways involved in tumor progression, molecularly tar-
geted therapies now represent an increasing proportion of new drugs
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entering clinical trials. In the case of breast cancer treatment, human-
ized antibodies have become a major option. For instance, the hu-
manized monoclonal antibody trastuzumab (Herceptin) represents
a successful adjuvant immunotherapy for the membrane receptor
Her2/Neu overexpressed in metastatic breast cancers [2,3]. Many
other therapeutic monoclonal antibodies were approved for use in
oncology target membrane proteins (e.g., CD20, CD33, and
CD52, for treatment of lymphomas, acute myelogenous leukemia,
and chronic lymphocytic leukemia, respectively). It is noteworthy,
yet not surprising, that many clinical biomarkers and therapeutic tar-
gets are cell surface proteins. Indeed, membrane proteins play impor-
tant roles in cell-matrix interactions, cell signaling and adaptation to
the environment. Herein, we sought to unveil potential molecular
cell surface markers, both on an invasive breast cancer cell line and
on its osteotropic metastatic variant. Different bone-seeking clones
were previously generated from the now well-described invasive cell
line MDA-MB-231 [4–6]. Peyruchaud et al. [6] were able to estab-
lish a breast cancer cell line subclone by repeated in vivo passages in
bone using the mouse heart injection model: this osteotropic clone,
MDA-MB-231-B02, is referred to as “B02” hereafter. On the basis
of the comparison of a transcriptomic analyses of MDA-MB-231 and
B02 cells, we recently showed that these osteotropic breast cancer
cells exhibit an osteomimetic phenotype [7]. However, because
mRNA and protein levels may differ [8,9], transcriptomic and pro-
teomic analyses remain complementary. For example, although the
αvβ3 integrin expression has been associated with the osteotropic
phenotype [10], there was no significant difference in the mRNA
transcript for this cell membrane receptor between the B02 clone
and the parent cell line [7]. We have therefore undertaken a compar-
ative membrane proteome survey between these two cell lines. Our
results showed that class I HLA and several cancer-associated markers
were down-regulated in the bone metastatic variant, whereas αv and
β3 integrins, among others, were up-regulated. Such differentially ex-
pressed proteins could be of major importance in unraveling the mech-
anisms of “homing” and could eventually represent potential new
molecular targets for new compounds aiming at selectively destroying
threatening cells (e.g., antibodies bound to bioactive molecules).
Materials and Methods
Cell Culture
The B02 cell line has been established from bone metastases
caused by MDA-MB-231. This subclone of MDA-MB-231 has been
selected after six in vivo passages in nude mice using a heart injection
model and is characterized by its unique predilection for bone me-
tastasis [6,10]. MDA-MB-231 and its derivative cell line B02 were
used at early passages until approaching confluency in RPMI 1640
medium (Invitrogen, Merelbeke, Belgium) supplemented with 10%
fetal calf serum (ICN, Asse Relegem, Belgium) at 37°C in a humid-
ified 5% CO2 incubator.
Cell Biotinylation
Cells were detached with dispase (Invitrogen). Cells were then
washed and resuspended at 106 cells/ml in D-PBS (Invitrogen).
Two reagents are of particular interest for the biotinylation of acces-
sible lysines: sulfosuccinimidyl-6-(biotin-amido) hexanoate (EZ-link
sulfo-NHS-LC-biotin; Pierce, Erembodegem-Aalst, Belgium) [11–
13], and sulfosuccinimidyl-2-(biotinamido) ethyl-1,3-dithiopropionate
(EZ-link sulfo-NHS-SS-biotin; Pierce) [11,14]. We found a signifi-
cant intracellular staining with sulfo-NHS-LC-biotin (as revealed by
streptavidin-conjugated to the Alexa 488 fluorescent dye used to vi-
sualize the subcellular distribution of labeled proteins), in good agree-
ment with Peirce et al. [11] (data not shown). We therefore used the
sulfo-NHS-SS-biotin reagent (0.2 mg/ml for 20 minutes at 4°C),
which also allowed the subsequent elution from the streptavidin resin
used for affinity purification. Each biotinylation reaction was stopped
by an incubation in 50 mM Tris in D-PBS (5 minutes).
Preparation of Membrane Fractions and Purification of
Biotinylated Proteins
Biotinylated cells were subjected to a freezing-thawing step, then
lysed in hypotonic CLB buffer (10 mM HEPES pH 7.5, 5 mM
EDTA, 10 mM NaCl, 1 mM KH2PO4, 5 mM NaHCO3, 1 mM
CaCl2, 0.5 mM MgCl2, 0.5 mM oxidized glutathione, and protease
inhibitors by 50 strokes of a tight-fitting Dounce homogenizer). The
homogenate was clarified by centrifugation (3000 rpm for 3 minutes
at 4°C) to generate a postnuclear supernatant. This latter fraction
was centrifuged again (35,000g for 30 minutes at 4°C) to yield a
membrane-enriched pellet. The efficacy of each step was checked
using light microscopy by mixing 5 μl of methyl green to 5 μl of
each fraction. The membrane-enriched pellet was solubilized in
1% Triton X-100 + 0.2% SDS in PBS and heated at 60°C for
10 minutes. Streptavidin-sepharose slurry (150 μl/mg of total pro-
teins; Amersham Biosciences, Diegem, Belgium) was equilibrated
by three washes in buffer A (1% NP-40 and 0.1% SDS in PBS),
and binding of biotinylated membrane proteins was allowed over-
night in a rotating mixer at 4°C. The resin was then washed twice
with buffer A, twice with buffer B (0.1% NP-40, 1 M NaCl in PBS),
twice with buffer C (0.1 M sodium carbonate in PBS, pH 11), and
once with PBS.
Binding of proteins biotinylated using EZ-Link sulfo-NHS-LC-
biotin to the resin and washing efficiencies were checked by SDS-
PAGE and were further checked either by Coomassie blue staining or
by blot analysis for the subsequent detection of biotin by streptavidin-
horseradish peroxidase (data not shown).
Elution of biotinylated proteins was performed for twice for 30min-
utes each at 58°C with 100 mMDTT in 1% SDS pH 7.0. Eluted pro-
teins were alkylated with 150 mM iodoacetamide (Sigma, Merelbeke,
Belgium) 30 minutes at RT in the dark. The eluate was then filtrated
through a sintered glass filter (10-μm pores; Pierce). After trichloro-
acetic acid precipitation and acetone washing, the pellet was dissolved
in 0.2% Rapigest (Waters, Zeek, Belgium) in 50 mM NH4HCO3.
Digestion with trypsin (1:100 trypsin-protein ratio; Promega, Leiden,
The Netherlands) was performed overnight at 37°C. Rapigest was
then cleaved by the addition of highly pure trifluoroacetic acid fol-
lowing manufacturer’s instructions.
Mass Spectrometry
Peptide separation was performed by reverse-phase liquid chroma-
tography on an Ultimate LC system (LC Packings, Amsterdam, The
Netherlands). The sample (5 μg in 20 μl at 0.25 μg/μl 0.1% formic
acid) was first trapped on an SCX micro precolumn [500 μm in inter-
nal diameter (i.d.), 15 mm in length, packed with MCA50 bioX-SCX
5 μm; LC Packings] at a flow rate of 30 μl/min followed by a micro
precolumn cartridge (300 μm in i.d., 5 mm in length, packed with
5μmC18 PepMap100; LC Packings). After 5minutes, the precolumn
was connected with the separating nanoflow column at 200 nl/min
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(75 μm in i.d., 15 cm in length, packed with 3 μm C18 PepMap100;
LC Packings) equilibrated in mobile phase A (0.1% formic acid in 2:98
of acetonitrile-degassed milliQ water). A linear elution gradient
was applied with mobile phase B (0.1% formic acid in 80:20 of
acetonitrile-degassed milliQ water) spanning from 10% to 40% in
95 minutes. The outlet of the LC system was directly connected to
the nanoelectrospray source of an EsquireHCT ion trapmass spectrom-
eter (Bruker Daltonics, Germany), controlled by Esquire Control v5.2
and Hystar v3.0 (from the Bruker Compass software bundle). For each
mass scan, a data-dependent scheme picked the three most intense dou-
bly or triply charged ions to be selectively isolated and fragmented in the
trap. The resulting fragments were analyzed using the Ultra Scan mode
(m/z range of 50-3000 at 26,000m/z per second). SCX-trapped peptides
were stepwise eluted with five salt concentrations (10, 20, 40, 80, and
200 mM), each followed by the same gradient of mobile phase B.
Data Processing and mgf File Generation
Raw spectra were formatted in DataAnalysis software (v3.4 build
150; Bruker Daltonics). The portions of the chromatogram-containing
signal were processed to extract and deconvolute MS/MS spectra,
without smoothing or background subtraction. Both deconvoluted
and undeconvoluted data were incorporated in the mgf file.
Database Searching
Proteins were identified using the minimally redundant SwissProt
human protein database [15] (release 54.5, SIB; Switzerland, 17,741
human entries), through the MS/MS ion search algorithm of the
Mascot search engine (Mascot and Mascot Daemon v2.1) [16] run-
ning on a local four-processor computer cluster. The mass tolerances
of precursor and fragmented ions were set at 0.6 and 0.3, respec-
tively; allowed modifications were partial oxidization of methionines,
carbamidomethyl cysteines, one misscut, and the ions’ score cutoff
was set to 30. The absolute probability (P) was set to .05. Interesting
proteins reported in Table 1 identified by only one peptide were
manually inspected using previously described criteria [17]. With
the above-mentioned parameters, 522 proteins were found in the
MDA cell line, whereas 526 were found in the B02 subclone. The
full protein list contained 691 proteins, of which 357 (68%) were
found in both cell lines.
The false-positive rate was estimated, for each sample, by dividing
the number of peptides found in the randomized SwissProt database
by the number of identified peptides from the normal SwissProt
database, according to following formula: fp = nrandom/nnormal, where
fp is the estimated false-positive rate, nrandom is the number of pep-
tides identified (queries after filtering) from the random SwissProt
database, and nnormal is the number of peptides identified (queries
after filtering) from the normal SwissProt database. Considering
the eight MS analyses performed for both MDA and B02, fp is equal
to 1.58 ± 0.30% (mean ± SEM).
Western Blot Analysis
MDA and B02 cells were lysed in RIPA extraction buffer (1%
NP-40, 0.5% deoxycholate, 0.1% SDS in 50 mM Tris pH 7.5,
150 mM NaCl) containing an anti–protease cocktail (Complete,
Roche, Vilvoorde, Belgium). Proteins were separated on 12.5% or
7.5% polyacrylamide gels under reducing conditions. Transfer was
performed overnight at 30 V. Membranes were blocked in TBS-
Tween (0.1% v/v) with 5% nonfat dried milk, and primary antibo-
dies were incubated overnight at 4°C.
Equal protein loading and transfer were assessed by the subsequent
use of an anti–alpha-tubulin antibody (clone B-5-1-2; Sigma) applied
on stripped membranes. Bound antibodies were visualized by in-
cubation of the membranes with ECL chemiluminescent substrate
Table 1. Selection of Membrane Proteins Identified in the MDA-MB-231 Cell Line (MDA, n = 4) and MDA-MB-231-B02 Cell Line (B02, n = 4).
Name MDA SC BO2 SC Biologic Process Cell. Component
CD51 (integrin αV) 1 3 3 4 Cell comm., Signal transd. PM
CD9 (MRP-1) 1 1 4 5 Immune resp. PM
Plasma cell membrane glycoprotein PC1 1 1 4 13 Metabolism energy pathways PM
Kinectin 1 4 4 19 Cell growth and/or maintenance ER, L
Prohibitin 1 7 4 27 Cell comm., Signal transd. MC, PM, N, EC, C
Moesin 3 35 3 26 Cell growth and/or maintenance PM, C, N
EGF receptor 4 12 4 26 Cell comm., Signal transd. PM, C
CD49b (integrin α2) 4 19 4 15 Cell comm., Signal transd. PM, C
Integrin β6 4 22 4 13 Cell comm., Signal transd. PM
Clathrin, heavy polypeptide 4 47 4 22 Cell growth and/or maintenance C, PM, G
CD44 4 61 4 29 Cell comm., Signal transd. –
CD98 4 68 4 68 Transport PM
CD29 (integrin β1) 4 162 4 60 Cell comm., Immune cell migr. PM
HLA-A 4 600 4 51 Immune resp. PM, ER, EC
CD49c (Integrin α3) 4 24 3 4 Cell comm., Signal transd. PM, C
CD155 (PVR) 1 1 0 0 Cell comm., Signal transd. PM, EC
CD104 (integrin β4) 1 7 0 0 Cell comm., Signal transd., Cell migration, Cell adhesion ITM
CD107b (LAMP2) 2 2 1 1 Cell growth and/or maintenance EC, ER, PM, G
CD49e (integrin α5) 3 8 1 1 Cell comm., Signal transd. PM
CD97 3 9 1 1 Cell comm., Signal transd. –
CD49f (integrin α6) 4 21 1 1 Cell comm., Signal transd. PM
HLA-C 4 374 0 0 Immune resp. PM
HLA-B 4 431 1 19 Immune resp. PM, EC
The proteins are identified from the SwissProt database with Mascot. The numbers in bold indicate in how many runs each protein was detected. Function and location of the proteins are determined
using the Human Protein Reference Database (www.hprd.org).
C indicates cytoplasm; Cell comm., cell communication; EC, extracellular; ER, endoplasmic reticulum; G , Golgi; Immune cell migr., immune cell migration; Immune resp., immune response; L, lysosome;
MC, mitochondrion; N , nuclear; PM, plasma membrane; SC, spectral counting (italicized numbers represent the number of redundant spectra identifying the same protein or group of protein, e.g.
HLA-A, -B, and -C serotypes); Signal transd., signal transduction.
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(Amersham Biosciences) and exposure to x-ray films (Fuji, Dussel-
dorf, Germany).
Antibodies
Mouse monoclonal anti–HLA class I antibody was from Sigma.
The antibodies anti-CD107b, anti-αv, and anti-β3 integrins were
from BD Biosciences (Erembodegem, Belgium).
Confocal Microscopy
MDA-MB-231 cells were biotinylated as described above or left
unlabeled, washed twice, and allowed to adhere to glass adhesion
slides. Adherent cells were fixed (3% paraformaldehyde for 10 min-
utes at RT), rinsed, blocked (1 mg/ml BSA in PBS), and incu-
bated with streptavidin-Alexa (1:4000 for 1 hour at RT in the
dark; Invitrogen/Molecular Probes, Merelbeke, Belgium). Cells were
visualized using a TCS SP laser scanning confocal microscope (Leica,
Groot Bijgaarden, Belgium).
FACS Analyses
Cells were washed twice in PBS and incubated with mouse immu-
noglobulin (IgG, 1 μl per 106 cells for 1 hour at 4°C). Cells were
then incubated (at 1:1000 dilution for 1 hour at 4°C) with fluores-
cein isothiocyanate–conjugated monoclonal secondary antibodies.
Cells were acquired using a FACSCalibur (Becton Dickinson) flow
cytometer and data analyzed using CellQuest software (BD Bio-
sciences) and FlowJo software (Tree Star, Inc., Ashland, OR).
Results
Membrane Biotinylation
To identify differentially expressed proteins between a well-known
parental invasive breast cancer cell line (MDA-MB-231) and its osteo-
tropic cell derivative (B02), we combined membrane protein labeling
and cell fractionation. Cell surface biotinylation provides an effec-
tive tool for the detection and purification of proteins and relies
on biotin labeling of solvent-exposed primary amines residues (i.e.,
lysines) on the membrane proteins [18]. To test for endogenous
and/or nonspecific binding of streptavidin-conjugated proteins, we
omitted the biotinylation step for both MDA (Figure 1A) and B02
(Figure 1C ). In these conditions, we did not detect any binding of
streptavidin-Alexa. Representative pictures of biotinylated mem-
branes of the parental cells and the osteotropic cells are shown in
Figure 1, B and D, respectively. After permeabilization, some intra-
cellular staining patterns appeared but were restricted to few cells.
Sample Processing
Figure 2 schematically depicts the method used in this study for
the identification of membrane proteins. After cell fractionation,
biotinylated proteins were captured on streptavidin resin, and after
thorough washes to remove abundant cytosolic proteins with both
high-salt and high-pH buffers [19], the proteins were eluted thanks
to the disulfide bonds between the lysines of labeled proteins and
the biotin moieties. Proteins were then submitted to proteolytic di-
gestion. Expression profiles of biotinylated proteins in the two human
Figure 1. Biotinylation of plasma membranes using sulfo-NHS-SS-biotin. MDA-MB-231 and MDA-MB-231-B02 were left unlabeled (A and
C, respectively), or biotinylated using sulfo-NHS-SS-biotin (B and D, respectively). Biotin labeling was revealed using streptavidin-Alexa
488. Nuclei were stained with TO-PRO-3 fluorescent dye. Confocal images were generated using a Leica TCS SP at an original magni-
fication of ×630. Data shown are representative pictures of repeated experiments.
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breast carcinoma cell lines were then determined using the Mul-
tidimensional Protein Identification Technology technique, based
on a two-dimensional separation of tryptic peptide digest using
nanoflow liquid chromatography coupled to electrospray tandem
mass spectrometry. To assess the specificity of the streptavidin col-
umn, nonbiotinylated breast cancer cells were processed identically
to the biotinylated ones and analyzed by MS. The number of iden-
tified proteins was much less in nonbiotinylated breast cancer cell
samples than in biotinylated samples. Proteins found in nonbiotin-
ylated samples (approximately 10 proteins, data not shown) were
most likely “sticky” proteins that unspecifically bound to the strepta-
vidin beads.
Table 1 shows a selection of membrane proteins identified with
high confidence from four different analyses of biotinylated MDA
samples and four different analyses of biotinylated B02 samples
(see Table W1 for sequences, scores, and total number of peptides
identifying these proteins of interest). The rationale used for protein
inclusion in Table 1 was the relevance of the proteins based on the
following: 1) the regulation of the proteins; 2) the actual presence of
the protein in the membrane fraction, as determined by checking in
the Human Protein Reference Database [20] (a database based on
experimental evidences manually extracted from the literature and
not on literature mining programs); and 3) the literature mining for
a most probable relevance of the proteins in cancer- or metastasis-
related events.
Regulation was assessed by both “on-off” and spectral counting
methods: for each analysis, a given protein was present or absent
(“on” or “off”). Whenever present, we used the associated spectral
counting (i.e., the number of redundant spectra of the same peptide)
as a quantification mean [21] to have an idea of the relative protein
abundance in the samples.
Down-regulation of HLAs
The most striking difference between the two human breast cancer
cell lines was clearly the down-regulation or absence of numerous
HLA (class I) proteins from the cell surface of the bone metastatic
variant B02 (Figure W1 shows a representative MS/MS fragmenta-
tion spectra of the peptide FIAVGYVDDTQFVR, identifying class I
HLAs). HLA-A are found in both cell lines, but the spectral counting
shows a huge down-regulation in B02. This down-regulation is also
true for HLA-B, and HLA-C was simply not found in the B02 MS
analyses. We sought to confirm this differential expression by FACS
(Figure 3) and Western blot analysis (Figure 4A) using an antibody
recognizing all class I HLAs. FACS analysis clearly shows that the
Figure 2. Schematic description of the method used in this study
for the identification of membrane proteins in the invasive human
breast cancer cell line MDA-MB-231 and its bone metastatic var-
iant MDA-MB-231-B02. Biotinylation was carried out by incubating
the cells in a solution containing a reactive ester that links biotin
to the free primary amines of membrane proteins. After cell frac-
tionation, biotinylated proteins are captured on streptavidin resin
and, after thorough washes, are eluted thanks to the disulfide
bond between the lysines and the biotin. Proteins are then submit-
ted to proteolytic digestion. Biotinylated proteins are then se-
quenced by shotgun mass spectrometry using nLC-ESI MS/MS.
Identified proteins differentially expressed in the cells are validated
by fluorescent-activated cell sorting (FACS; Figure 3) or Western
blot analysis (WB; Figure 4).
Figure 3. FACS analysis of class I HLA proteins in MDA and B02
cell lines. MDA and B02 cells were labeled either with class I HLA
antibody and analyzed with a FACSCalibur (BD Biosciences). Neg-
ative controls (−) are shown in black, B02 in dark gray, and MDA in
light gray.
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HLA proteins are down-regulated in B02, confirming the data ob-
tained from mass spectrometry. The Western blot unambiguously
also shows that a huge difference actually exists between the two cell
lines, with a prominent HLA expression in MDA.
We also checked the expression of some other proteins to validate
the MS data. We investigated the expression levels of three CD mark-
ers, CD107b, CD51, and CD61, all three proteins being involved in
tumorigenesis and/or metastasis. The expression levels were assessed
by Western blot analysis, as shown in Figure 4, B, C , and D, for
CD107b, CD51, and CD61, respectively. The actual expression of
these proteins was validated for each CD marker, confirming that the
MS analyses were able to depict correctly global protein expression
patterns of the parental versus the osteotropic cell line.
Discussion
The ability of cancer cells to grow in a specific site depends not
only on features that are inherent to cancer cell but also on features
that are inherent to the organ and on the interactions between cancer
cells and the metastatic site. These interactions are most probably
essential in determining whether the cancer cells have a high or low
probability of growing. In this regard, the up- or down-regulation
of membrane-associated proteins involved in the cross talk between
circulating invasive cells and the organs might be important for the
establishment of metastases. Using cell surface labeling and a high-
throughput proteomic method, we have identified differentially
expressed proteins between two cell lines that could be of special
interest in characterizing the osteotropic phenotype. We analyzed
the membrane proteome of the bone-seeking B02 cell line, selected
by multiple in vivo passages from the parental breast cancer cell line
MDA-MB-231. The methodology used enabled us to discover sev-
eral differentially expressed proteins. This shotgun approach permits
fast and accurate identification of small but complex biologic sam-
ple mixtures, overcoming many limitations of two-dimensional gel
electrophoresis for proteome analysis [22]. A quite similar method
was already used to compare MCF7 and BT474 breast cancer cell
lines but did not include cell surface biotinylation [23]. It might be
also useful to benefit from direct protein quantitation using, for
instance, stable isotopic labeling with amino acids in cell culture.
However, we showed herein that Multidimensional Protein Identi-
fication Technology, a technique now well established in many MS
laboratories, is sufficient for identifying differentially expressed
membrane proteins and even estimate the protein abundance [21].
More difficult to set up and also more expensive technologies such
as stable isotopic labeling with amino acids are not absolutely needed
yet can provide interesting additional data [24].
Our approach led to the discovery of proteins that are either up-
regulated or down-regulated in the B02 cell line. For instance, B02
cells overexpressed the αvβ3 integrins when compared to the parental
cell line. This was an expected result knowing the unanimously recog-
nized role of these integrins during bone metastasis development: αvβ3
integrins confer to breast tumor cells a greater propensity to metasta-
size to bone [10], can even promote spontaneous metastasis of breast
cancer cells to bone [25,26], and represents a therapeutic target for
the treatment of experimental bone metastases [26]. Because this over-
expression was not revealed at the transcriptomic level [7], these data
confirm the additional and complementary value of the proteomic
approach to the transcriptomic analysis. Three other interesting pro-
teins were found up-regulated in the B02 clone followingMS analyses.
The first one is prohibitin, a multifunctional membrane-associated
protein that was interestingly found up-regulated in superinvasive
cancer cells [27]. Its molecular function as a transmembrane signaling
receptor is still elusive [28]. This protein would deserve further inves-
tigations in bone metastases, because direct intratumoral injection of
prohibitin 3′UTR RNA can cause complete regression of tumors and
metastases [29]. The second protein up-regulated in B02 is MRP-1, a
cell surface glycoprotein that is known to complex with integrins [30].
This protein can modulate key events, such as cell adhesion, migra-
tion, proliferation, and growth, and might be of special interest in
the bone tropism. The third protein up-regulated in the B02 cell
line is kinectin, an evolutionary conserved integral membrane protein
[31]. Less is known about kinectin in cancer, but kinectin was at
least found to be alternatively spliced in hepatocellular carcinoma
[32]. All these proteins would deserve further investigations.
Other proteins were found down-regulated in the B02 cells. The
most important finding is the strong down-regulation of MHC
(HLA) class I in the bone-seeking clone. It has already been shown
that escape caused by deficient expression of MHC class I antigens
on tumor cells may support homing or survival of disseminated tumor
cells in lymphoid tissue [33]. Similarly, reduced MHC class I expres-
sion was found in metastatic cells from the bone marrow of patients
with squamous cell carcinoma of the head and neck region [34]. It has
been suggested that the lack of MHC class I expression is a potential
mechanism to escape from HLA class I–restricted lysis by cytotoxic T
cells. This escape from immunity could therefore explain at least in
part the establishment of B02 clones in the bone environment.
Others proteins were found to be down-regulated in the B02 cell
line, such as CD107b, also known as lysosomal-associated membrane
protein 2. This protein is a heavily glycosylated transmembrane pro-
tein, whose up-regulation on the surface of tumor cell lines has been
associated with an enhanced metastatic potential by increasing adhe-
sion to extracellular matrix and endothelium [35].
To summarize, we searched for proteins that could play a role in
the establishment of circulating cancer cells in the bone environment,
Figure 4.Western blot analyses. The different proteins revealed by
mass spectrometry were probed with their respective antibodies
after Western blot analysis: expression of class I HLA (A), CD107b
(B), CD51 (integrins αV; C), and CD61 (integrin β3; D) are shown,
and the amount of proteins loaded (20 μg) was normalized using
tubulin alpha (E).
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by comparing the membrane proteome of osteotropic cells versus the
parental cell line. The down-regulation of class I HLAs contribute
most likely to the establishment of B02 cells in the bone environ-
ment by preventing immunity responses against these cancer cells.
On the other side, up-regulation of membrane proteins from circu-
lating metastatic cells can constitute potentially important targets for
antibody-based anticancer treatments.
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Figure W1. (A) Manually annotated MS/MS fragmentation spectrum of the peptide FIAVGYVDDTQFVR (from the doubly charged parent
peptide at m/z 815.348, blue diamond), identifying human HLA class I histocompatibility antigen, followed by the MS/MS fragmentation
spectrum annotated by the Mascot software (B). The table below the fragmentation spectra (C) shows ions from the b and y series.
Table W1. Sequences, Scores, and Total Number of Peptides Identifying Proteins of Interest.
Proteins of
Interest
Peptides MDA-MB-231: Number of
Peptides (and Mascot Scores)
B02: Number of Peptides
(and Mascot Scores)
#1 #2 #3 #4 #1 #2 #3 #4
CD51 SSASFNVIEFPYK 1 (60)
IYIGDDNPLTLIVK 2 (91; 92) 1 (62)
AGTQLLAGLR 1 (51)
STGLNAVPSQILEGQWAAR 1 (54)
LTPITIFMEYR 1 (33)
CD9 KDVLETFTVK 1 (74) 1 (63) 1 (45) 2 (74; 61) 1 (70)
Kinectin SVLAETEGILQK 1 (90) 2 (55, 91)
SVEELLEAELLK 1 (74) 1 (33) 1 (50) 4 (45; 72; 75; 60)
DAVSNTTNQLESK 1 (45) 1 (86)
WLQDLQEENESLK 1 (62) 2 (57; 58)
VQELQNLLK 1 (61) 1 (43)
AQQSLELIQSK 1 (64) 2 (38; 49)
IHVSYQETQQMQMK 1 (39)
AAGDTTVIENSDVSPETESSEK 1 (75)
LSDALAVEDDQVAPVPLNVVETSSSVR 1 (39)
Prohibitin FDAGELITQR 1 (70) 3 (32;
38; 68)
3 (75; 87; 81)
VLPSITTEILK 1 (46) 1 (39) 1 (30) 1 (30) 2 (30; 37)
IFTSIGEDYDER 3 (60;
60; 62)
1 (43) 2 (60; 42)
NITYLPAGQSVLLQLPQ 1 (36; 62) 1 (94)
DLQNVNITLR 1 (46) 2 (34; 76)
AAELIANSLATAGDGLIELR 1 (49) 3 (68; 50; 72) 3 (112; 76; 62)
KLEAAEDIAYQLSR 1 (34) 1 (111)
CD107b IPLNDLFR 1 (48) 1 (66) 1 (48)
Class I HLA VDLGTLR 1 (42) 1 (39)
FDSDAASQR 1 (78)
YFFTSVSR 3 (66;
60; 56)
1 (33)
WEAAHVAEQLR 3 (71;
31; 62)
1 (51)
MYGCDVGSDWR 3 (47;
80; 80)
2 (57; 73)
YFYTAVSR 1 (47)
MYGCDLGPDGR 1 (66)
WAAVVVPSGEEQR 5 (61; 44;
61; 61; 61)
1 (43) 2 (61; 62) 2 (40; 33) 1 (55)
SWTAADTAAQITQR 4 (52; 63;
36; 94)
4 (39; 45;
50; 73)
4 (46; 36;
50; 34)
2 (91; 52)
AYLEGECVEWLR 3 (69;
65; 75)
FITVGYVDDTLFVR 3 (111;
110; 59)
3 (44;
65; 79)
MYGCDVGPDGR 2 (68; 35)
TYLEGTCVEWLR 1 (41)
SWTAADMAAQTTK 2 (64; 50) 3 (96;
100; 78)
WAAVVVPSGQEQR 7 (58; 39;
44; 62;
44; 32; 50)
8 (45; 61;
41; 37;
62; 50;
44; 44)
2 (50; 50) 3 (39;
44; 62)
4 (40; 38;
48; 44)
1 (44) 1 (61)
AYLEGTCVEWLR 20 (48; 77;
78; 78;
86; 83;
74; 84;
82; 46;
89; 80;
85; 63;
86; 76;
64; 49;
61; 47)
1 (43) 2 (71; 84)
FIAVGYVDDTQFVR 20 (50; 41;
83; 90;
61; 90;
97; 75;
93; 78;
90; 89;
54; 96;
90; 93;
89; 80;
65; 75)
13 (96; 107;
98; 98;
53; 90;
57; 99;
89; 97;
90; 97; 66)
12 (84; 102;
56; 86;
98; 97;
96; 31;
54; 98;
72; 72)
1 (81) 4 (103; 92;
106; 87)
1 (81)
Table W1. (continued )
Proteins of
Interest
Peptides MDA-MB-231: Number of
Peptides (and Mascot Scores)
B02: Number of Peptides
(and Mascot Scores)
#1 #2 #3 #4 #1 #2 #3 #4
APWIEQEGPEYWDGETR 6 (68; 76;
74; 61;
31; 42)
8 (97; 51;
82; 50;
57; 49;
81; 36)
6 (40; 81;
79; 63;
81; 42)
4 (96; 104;
90; 54)
1 (60)
GGSYSQAACSDSAQGSDVSLTA 2 (41; 42)
KGGSYSQAASSDSAQGSDVSLTACK 2 (85; 81) 2 (93; 56) 1 (42) 1 (77)
DGEDQTQDTELVETR 1 (75) 3 (72;
73; 81)
2 (33; 48)
DGEDQTQDTELVETRPAGDR 2 (41; 42) 1 (43) 2 (48; 33)
DGEDQTQDTELVETRPAGDGTFQK 1 (56) 4 (32; 39;
44; 32)
3 (52;
30; 41)
1 (30) 3 (31;
46; 33)
1 (45)
GGSYSQAASSDSAQGSDVSLTACK 1 (98) 1 (75)
APWIEQEGPEYWDR 1 (65) 1 (49)
For each protein of interest, the total number of peptides is given for each experiment (n = 4 for MDA-MB-231 and n = 4 for B02 cell line, from four different MDA vs B02 analyses). The numbers in
parentheses represent the Mascot scores (rounded down to the nearest number). For class I HLA, a subset of nonredundant peptides has been selected for the sake of clarity.
